SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as the biotech community intensely anticipates the imminent Phase 3 REGAL trial results for its AML immunotherapy, GPS, with many interpreting the extended trial duration as a strong indicator of "curative outcomes" and openly battling bearish sentiment, fueling expectations for a substantial short squeeze and a potential blockbuster buyout.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is gaining attention as escalating geopolitical tensions, particularly regarding Iran and broader U.S.-China dynamics, intensify the focus on securing domestic heavy rare earth supplies for defense and high-tech industries. The community is actively anticipating the company's upcoming Bankable Feasibility Study, expected to re-rate its Greenland-based Tanbreez project's strategic value amidst calls for Western supply chain independence.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is surging as intense short-covering and robust institutional accumulation are fueled by renewed optimism for its FDA-approved TIL therapy, Amtagvi, and imminent data readouts for pipeline expansion in lucrative oncology indications. The community widely anticipates a significant re-rating, potential international approvals, and strategic buyout interest, highlighting its perceived undervaluation.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is experiencing extreme volatility, with an initial market surge driven by community discussion around a White House briefing suggesting a resolution to the Iran conflict, now tempered by conflicting reports and concerns over escalating oil prices.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is trending with high anticipation for its upcoming earnings report, as its recent AIUC-1 certification highlights its role in secure enterprise AI agent orchestration, driving polarized community discussion and short-squeeze speculation.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is actively discussed following reports of a potential major aircraft order from China and heightened demand for defense products amid geopolitical tensions, balancing this against community concerns over commercial order delays from rising fuel costs and ongoing production challenges.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending after its Q4 earnings showcased robust e-commerce and advertising revenue growth, coupled with a substantial share repurchase and dividend increase, positioning the retail giant as a defensive play. The community is buzzing over its evolving business model and potential benefits from recent tariff rulings, though some debate its current valuation amidst broader market volatility.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum is trending due to a steady stream of new, large contracts in nuclear energy, space systems, and defense, which continues to build its substantial $47+ billion backlog. While some in the community express frustration over the stock's recent performance, many anticipate significant long-term growth from its critical government and infrastructure services, especially after recent analyst upgrades.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending after being selected for the White House-backed eVTOL Integration Pilot Program, paving the way for early U.S. air taxi operations, and launching Uber Air in Dubai with commercial service anticipated by 2026. The community is actively discussing these significant commercialization milestones, alongside recent Q4 revenue beats and institutional buying, as crucial steps for its long-term potential in the burgeoning air mobility sector.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is trending after exceeding Q1 earnings expectations, propelled by soaring networking revenue from its Juniper integration and strong AI demand that led to raised full-year guidance. The community highlights HPE's strategic shift toward higher-margin AI and networking infrastructure, expecting continued growth and potential re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics (CADL) Projected to Post Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) Director Paul Manning bought 550,458 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was bought at an...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat...

Why Is Candel Therapeutics Stock Falling Friday?

Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therapies and development costs.read more...

Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers Grail, Candel Therapeutics, Copart In Focus

U.S. stock futures rose on Friday after closing lower on Thursday. Futures of all the major benchmark indices were positive. Wall Street is waiting for the fourth-quarter GDP data, scheduled for...

<ul class="summary-bullets"><li>The $100 million equity raise is expected to fund commercialization preparations for CAN-2409 in early-stage, localized prostate cancer.</li><li>Candel also plans to use part of the funds to support the ongoing phase 3 trial of CAN-2409 in non-small cell lung cancer.</li><li>RTW is set to receive a tiered single-digit percentage of U.S. net sales, subject to a cap.</li></ul>Shares of Candel Therapeutics, Inc. (CADL) fell 14% in extended trading on Thursday, after the company outlined plans for a $100 million public stock offering, outweighing a $100 million royalty funding agreement announced the same day.<h2 class="st-heading-2">Candel Launches $100M Public Offering</h2>Candel said it has launched an underwritten public offering of $100 million of its common stock. The underwriters have also been granted a 30-day option to purchase up to an additional $15 million in shares on the same terms.According to the company, the proceeds will go toward preparing for the potential launch of Aglatimagene Besadenovec, also known as CAN-2409, in early-stage, localized prostate cancer. This includes medical affairs, launch readiness and other commercialization-related work. Candel also plans to use part of the funds to support the ongoing phase 3 trial of CAN-2409 in non-small cell lung cancer.<h2 class="st-heading-2">RTW Royalty Deal Adds $100M In Funding</h2>Earlier in the day, Candel separately disclosed a $100 million royalty funding agreement with funds managed by RTW Investments. The deal will support a potential U.S. launch of CAN-2409 in intermediate to high-risk localized prostate cancer.The royalty financing is tied to regulatory progress. It will become available upon approval of CAN-2409 by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, RTW would receive a tiered single-digit percentage of annual U.S. net sales of the therapy, subject to a cap.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CADL was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cadl_ss_png_cea4ebff8f.webp" alt="cadl ss.png" width="977" height="147"><figcaption>CADL sentiment and message volume as of February 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Araman44/message/645398070">said</a>, “At the end of the day, this stock has lots of potential due to its pipeline. Trade away as needed. Just don’t be surprised when it flies.”<stembedurl>https://stocktwits.com/Araman44/message/645398070</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/CO145/message/645397862">said</a> they want to see RTW participate in the deal alongside other “prominent” biotech investors, including Manning and “high-quality” institutional funds such as T. Rowe Price. “If we see this, the stock will perform well finally. I do not want to see CVI, Susquehanna, or any of these low-quality players,” they added.<stembedurl>https://stocktwits.com/CO145/message/645397862</stembedurl>CADL stock has risen 5% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CADL stock has risen 5% so far this year. (Photo credit: Getty Images)

Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today

Candel is pushing ahead with an equity raise and also lined up $100 million in royalty funding from RTW Investments, contingent on FDA approval of CAN-2409.

Equity

Candel Therapeutics (NASDAQ:CADL) Trading 3.9% Higher - Should You Buy?

Candel Therapeutics (NASDAQ:CADL) Trading Up 3.9% - What's Next...

Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research

Zacks Research cut shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday...

New Strong Sell Stocks for January 20th

DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CADL News

CADLCandel Therapeutics Inc